Trends in gabapentin and baclofen exposures reported to U.S. poison centers
(2019). Trends in gabapentin and baclofen exposures reported to U.S. poison centers. Clinical Toxicology. Ahead of Print.
Related Articles
Endotheliopathy in systemic sclerosis: from endothelium-dependent vasodilation to the dysfunction of the vascular reserve, is the paradise lost? – Arthritis Research & Therapy
Microvascular dysfunction is considered one of the main pathogenetic pathways in systemic sclerosis (SSc), and endothelial cells plays a pivotal role even in the early…
Is Lupus Just a B Cell Disorder? | RheumNow
I’m very happy to give you some insights entitled, “Is Lupus a B-Cell Disorder”. I will review some aspects, mainly pros and cons, but at…
A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis | RheumNow
Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses…
Systematic review and meta-analysis of the efficacy of biologic and targeted synthetic therapies in sarcoidosis
Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents,…
The race to reset autoimmune diseases
Nature Reviews Drug Discovery – Discover the world’s best science and medicine | Nature.com
Panacea of Prednisone & Cannabis (5.16.2025) | RheumNow
Dr. Jack Cush reviews the news, journal and regulatory reports from this week on RheumNow.com. Interesting trends and results with prednisone in lupus, cannabis in…
Endotheliopathy in systemic sclerosis: from endothelium-dependent vasodilation to the dysfunction of the vascular reserve, is the paradise lost? – Arthritis Research & Therapy
Microvascular dysfunction is considered one of the main pathogenetic pathways in systemic sclerosis (SSc), and endothelial cells plays a pivotal role even in the early…
A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis | RheumNow
Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses…